Margrit Marti

Margrit Marti's practice focuses on mergers & acquisitions, private equity and venture capital. She also advises clients on IPOs and other equity capital markets transactions as well as in matters of corporate law, securities regulation and corporate governance.

• Advised Windward Bio on its USD 200 m Series A financing
• Advised EQT on its sale of 10% in Galderma to L'Oréal
• Advised Galderma on its IPO on SIX Swiss Exchange
• Advised VectivBio (Nasdaq: VECT) with respect to the public cash tender offer from Ironwood Pharmaceuticals (USD 1 billion), and previously on VectivBio's follow-on public offerings and concurrent private placement and its IPO on Nasdaq
• Advised Noema Pharma on its USD 112 million Series B financing round
• Advised AMF Medical and its shareholders on the USD 200 million sale to Tandem Diabetes Care

• Capital markets: Equity
• M&A
• Private equity

• Consumer goods and services
• Financial services
• Healthcare
• Pharma and life sciences
• Tech and telecoms

• Swiss Bar Association 
• Zurich Bar Association
• International Bar Association

• LL.M., Certificate in Business Law, University of California, Berkeley (2015)

• M.A. HSG in Law, University of St. Gallen (2009)